Rep. Katie Porter (D-Calif.) never wastes an opportunity to roast a CEO.
On Wednesday, three pharmaceutical executives, including former Celgene CEO Mark Alles, testified on drug pricing for the House Oversight Committee. While at the company, Alles saw a massive increase in the price of the cancer drug Revlimid — and Porter broke down just what it got Alles in return.
Porter started her takedown by asking Alles if he knew what a Revlimid pill cost in 2005: $215, she reminded him with the help of a whiteboard. And by the time Alles left the company late last year, after its sale to Bristol-Myers Squibb, a single Revlimid pill cost $763. "Did the drug get substantially more effective in that time? Did cancer patients need fewer pills?" Porter questioned, trying to figure out why Celgene upped the price. Alles answered by saying Revlimid proved effective in more patients. "So you discovered more patients who might benefit from paying $763 a pill?" Porter rhetorically responded, outlining how the average senior in her district couldn't even afford one pill.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Porter then moved on to tear apart the $13 million Alles made in 2017 as Celgene's CEO. "It's 200 times the average American's income and 360 times what the average senior makes on Social Security," Porter noted. She then reminded Alles just how he made "half a million dollars, personally, just by tripling the price of Revlimid." "The drug didn't get any better, the cancer patients didn't get any better, you just got better at making money," Porter concluded. Watch her questioning below. Kathryn Krawczyk
-
How will the new Repayment Assistance Plan for student loans work?the explainer The Repayment Assistance Plan (RAP) will replace existing income-driven repayment plans
-
In the Spotlight Venezuelan President Nicolás Maduro has been at odds with US forces
-
Music reviews: Ethel Cain, Amaarae, and The Black KeysFeature "Willoughby Tucker, I'll Always Love You," "Black Star," and "No Rain, No Flowers"
-
Trump said to seek government stake in IntelSpeed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to ChinaSpeed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with DisneySpeed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B dealSpeed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance mergerSpeed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profitsSpeed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new highSpeed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliablespeed read The Labor Department is collecting less data for its consumer price index due to staffing shortages
